Möchten Sie immer auf dem neuesten Stand bleiben?

LYON, France, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine company, today announced the signing of an agreement with Seqirus, the second...

Signing of the finance contract by EIB Vice-President Ambroise Fayolle and Valneva's management board to take place today during a ceremony at the EIB's Paris offices Valneva will use the...

Valneva Announces Successful Outcome of its AGM; The Company Confirms its Growth Strategy and Financial Outlook New Supervisory Board appointed - consisting of five re-elected and three new...

Valneva Appoints Two Leading Pharma Executives to its Supervisory Board LYON, France, July 1, 2016 (GLOBE NEWSWIRE) -- Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine...

First sales of Flu Vaccines Produced on Valneva's EB66 ®  Cell-Line Valneva to begin receiving royalties for an EB66®-based human vaccine in 2016 LYON, France, June 13, 2016...

LYON, France, March 16, 2016 (GLOBE NEWSWIRE) -- Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine company, announces today the signing of a $42 million contract with the US...

Valneva Posts 96% Revenue Growth in 2015;  Forecasts 2016 Revenues of €90 to €100 Million The Company today announced its unaudited FY 2015 revenues, unaudited year-end cash...

Valneva to supply process development services for EB66®-based Influenza vaccines Advanced Development program sponsored by the US Department of Health and Human Services Valneva to...

Business transition and integration of the newly acquired DUKORAL® and Nordics vaccine distribution business largely completed Health Canada requested changes to product monograph for...

LYON, France, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Valneva SE ("Valneva"), a leading pure-play vaccine company, announced today that its fully owned US subsidiary Intercell USA, Inc.  has entered...